Skip to content

Released Aug 4, 2016, after the close

10-Q filed Aug 4, 2016, 35 days after period end · 0001193125-16-671775

Q2 2016 · 10-Q
Revenue$59.00K−60.7% vs Q2 2015no prior Q1 2016 on file
Net Income-$30.16MN/M vs Q2 2015N/M vs Q1 2016
EPS Diluted-$0.84N/M vs Q2 2015N/M vs Q1 2016
Operating Income-$30,476,000N/M
Operating Cash Flowderived-$20,894,000N/M
Free Cash Flowderived-$20,900,000N/M
Margins · derived
Operating margin-51654.2%−29645.6 pt vs Q2 2015
Net margin-51115.3%−29318.6 pt vs Q2 2015

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ2 2016Q2 2015Q2 2014Q2 2013
Revenue$59.00K$150.00K$21.00K$133.00K
Net Income-$30.16M-$32.70M-$16.43M—
EPS Diluted-$0.84-$0.92-$0.55-$2.86

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Karyopharm Therapeutics Inc. · CIK 1503802 · Engraved from SEC EDGAR